The S&P 500 slid 0.1% on Thursday, Aug. 7, 2025, as new tariffs took effect, raising import duties on goods from numerous U.S ...

Shares of Eli Lilly (NYSE: LLY) were plunging 14.8% as of 11:14 a.m. ET on Thursday. The big drugmaker reported results for ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...

Now, new clinical trial results suggest that an oral form of this medication may be coming soon—and the results so far are ...

Shares of Eli Lilly & Co. suffered their biggest selloff in 26 years on Thursday, after the drug giant disclosed late-stage trial data for its weight-loss pill that fell well short of expectations.

GLP-1's, which are traditionally diabetes medications, have exploded in popularity since they were approved for weight-loss.

A slew or company results were causing big market moves ahead of the opening bell Thursday, and for many, earnings-beat wasn’t enough to prevent a selloff.

The main indexes finished well off their session highs after a disappointing batch of corporate earnings reports.

U.S. stocks are drifting lower after President Donald Trump’s latest tariffs took effect on dozens of countries, but the moves are modest and stocks rose in much of the rest ...

The iPhone maker's shares [rallied for a second day]( ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Eli Lilly & Biogen's Alzheimer's drugs may offer minimal impact despite aggressive marketing. Click here to get insights on ...